SciNeuro and Eli Lilly Unite on Antibodies to Defeat Neurological Diseases in China
Published: Apr 14, 2021 By Mark Terry Shanghai, China-based SciNeuro Pharmaceuticals and U.S.-based Eli Lilly and Company inked an exclusive license deal to develop and commercialize alpha-synuclein targeted antibody treatments in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. SciNeuro picked up an exclusive license to the antibodies developed by Lilly. Under the terms of the deal, SciNeuro is paying Lilly cash upfront as well as various milestone payments and ...
Hong Kong Michael Hutton Eli Lilly Us Basedeli Lilly Neurodegeneration Research Lilly Asia Ventures Fund
Source: biospace.com